# Inhibitory immune checkpoints suppress the surveillance of senescent cells promoting their accumulation with aging and in age-related diseases

**Authors:** Antero Salminen

PMC · DOI: 10.1007/s10522-024-10114-w · 2024-07-01

## TL;DR

The paper suggests that immune checkpoints like PD-L1 help senescent cells avoid immune detection, leading to their accumulation during aging and age-related diseases.

## Contribution

The paper proposes that inhibitory immune checkpoints may be a novel mechanism for senescent cell immune evasion.

## Key findings

- Senescent cells express PD-L1 and other inhibitory checkpoint ligands.
- PD-L1 on senescent cells suppresses cytotoxic T and NK cell activity.
- Immune checkpoint signaling may prevent elimination of senescent cells.

## Abstract

The accumulation of pro-inflammatory senescent cells within tissues is a common hallmark of the aging process and many age-related diseases. This modification has been called the senescence-associated secretory phenotype (SASP) and observed in cultured cells and in cells isolated from aged tissues. Currently, there is a debate whether the accumulation of senescent cells within tissues should be attributed to increased generation of senescent cells or to a defect in their elimination from aging tissues. Emerging studies have revealed that senescent cells display an increased expression of several inhibitory immune checkpoint ligands, especially those of the programmed cell death protein-1 (PD-1) ligand-1 (PD-L1) proteins. It is known that the PD-L1 ligands, especially those of cancer cells, target the PD-1 receptor of cytotoxic CD8+ T and natural killer (NK) cells disturbing their functions, e.g., evoking a decline in their cytotoxic activity and promoting their exhaustion and even apoptosis. An increase in the level of the PD-L1 protein in senescent cells was able to suppress their immune surveillance and inhibit their elimination by cytotoxic CD8+ T and NK cells. Senescent cells are known to express ligands for several inhibitory immune checkpoint receptors, i.e., PD-1, LILRB4, NKG2A, TIM-3, and SIRPα receptors. Here, I will briefly describe those pathways and examine whether these inhibitory checkpoints could be involved in the immune evasion of senescent cells with aging and age-related diseases. It seems plausible that an enhanced inhibitory checkpoint signaling can prevent the elimination of senescent cells from tissues and thus promote the aging process.

## Linked entities

- **Proteins:** PDCD1 (programmed cell death 1), CD274 (CD274 molecule), LILRB4 (leukocyte immunoglobulin like receptor B4), KLRC1 (killer cell lectin like receptor C1), HAVCR2 (hepatitis A virus cellular receptor 2), SIRPA (signal regulatory protein alpha)

## Full-text entities

- **Genes:** KLRC1 (killer cell lectin like receptor C1) [NCBI Gene 3821] {aka CD159A, NKG2, NKG2A}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, SIRPA (signal regulatory protein alpha) [NCBI Gene 140885] {aka BIT, CD172A, MFR, MYD-1, MYD1, P84}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, LILRB4 (leukocyte immunoglobulin like receptor B4) [NCBI Gene 11006] {aka B4, CD85K, ILT-3, ILT3, LIR-5, LIR5}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** age-related diseases (MESH:D010024), inflammatory (MESH:D007249), cancer (MESH:D009369)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11374851/full.md

---
Source: https://tomesphere.com/paper/PMC11374851